M. Beylot‐Barry

15.6k total citations
337 papers, 5.7k citations indexed

About

M. Beylot‐Barry is a scholar working on Dermatology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, M. Beylot‐Barry has authored 337 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Dermatology, 117 papers in Pathology and Forensic Medicine and 111 papers in Epidemiology. Recurrent topics in M. Beylot‐Barry's work include Cutaneous lymphoproliferative disorders research (130 papers), Lymphoma Diagnosis and Treatment (77 papers) and Psoriasis: Treatment and Pathogenesis (42 papers). M. Beylot‐Barry is often cited by papers focused on Cutaneous lymphoproliferative disorders research (130 papers), Lymphoma Diagnosis and Treatment (77 papers) and Psoriasis: Treatment and Pathogenesis (42 papers). M. Beylot‐Barry collaborates with scholars based in France, United States and Germany. M. Beylot‐Barry's co-authors include B. Vergier, Jean‐Philippe Merlio, C Beylot, M.‐S. Doutre, Anne Pham‐Ledard, P. Joly, F. Aubin, M. Delaunay, M. D’Incan and Florent Grange and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

M. Beylot‐Barry

298 papers receiving 5.5k citations

Peers

Countries citing papers authored by M. Beylot‐Barry

Since Specialization

Citations

This map shows the geographic impact of M. Beylot‐Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Beylot‐Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Beylot‐Barry more than expected).

Fields of papers citing papers by M. Beylot‐Barry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Beylot‐Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Beylot‐Barry. The network helps show where M. Beylot‐Barry may publish in the future.

Co-authorship network of co-authors of M. Beylot‐Barry

This figure shows the co-authorship network connecting the top 25 collaborators of M. Beylot‐Barry. A scholar is included among the top collaborators of M. Beylot‐Barry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Beylot‐Barry. M. Beylot‐Barry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors 2025 ·British Journal of Dermatology ·L. Dousset, (unknown), (unknown), Benjamin Dartigues, (unknown), Walid Mahfouf, (unknown), Benoı̂t Rousseau, Nívea Dias Amoêdo, Stéphane Claverol, (unknown), (unknown), Marie‐Laure Jullié, B. Vergier, Alain Taı̈eb, Laure Favot, Rodrigue Rossignol, M. Beylot‐Barry, Macha Nikolski, (unknown)	0
2	Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors 2023 ·European Journal of Cancer ·(unknown), S. Prey, Caroline Dutriaux, E. Gérard, Anne Pham‐Ledard, M. Beylot‐Barry, Marie Kostine	3
3	Spotlight on hTERT Complex Regulation in Cutaneous T-Cell Lymphomas 2023 ·Genes ·(unknown), Martina Prochazkova‐Carlotti, Rui Batısta, Ana Pestana, (unknown), Jacky Ferrer, (unknown), David Cappellen, Cecília Durães, Paula Boaventura, João Vinagre, Lamia Azzi‐Martin, Sandrine Poglio, José Cabeçadas, Manuel Campos, M. Beylot‐Barry, Manuel Sobrinho‐Simões, Jean‐Philippe Merlio, Paula Soares, Edith Chevret	3
4	Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome 2022 ·Journal of the European Academy of Dermatology and Venereology ·M. Beylot‐Barry, Nina Booken, Carsten Weishaupt, Julia Scarisbrick, (unknown), (unknown), (unknown)	12
5	Changes in total skin electron beam therapy modalities for mycosis fungoides: A single-centre study 2022 ·Annales de Dermatologie et de Vénéréologie ·(unknown), Anne Pham‐Ledard, (unknown), M. Beylot‐Barry	3
6	Primary intralymphatic histiocytosis: Case report and literature review 2022 ·Annales de Dermatologie et de Vénéréologie ·(unknown), (unknown), (unknown), (unknown), M. Beylot‐Barry, Anne Pham‐Ledard	0
7	Telomeric Repeat-Containing RNA (TERRA): A Review of the Literature and First Assessment in Cutaneous T-Cell Lymphomas 2022 ·Genes ·(unknown), (unknown), (unknown), Martina Prochazkova‐Carlotti, (unknown), Jacky Ferrer, Chantal Farra, M. Beylot‐Barry, Jean‐Philippe Merlio, Edith Chevret	15
8	Clinical features associated with the invasive component in lentigo maligna of the head and neck: A retrospective study of 175 cases 2022 ·Annales de Dermatologie et de Vénéréologie ·E. Gérard, O. Cogrel, (unknown), (unknown), (unknown), Anne Pham‐Ledard, Caroline Dutriaux, (unknown), B. Vergier, M. Beylot‐Barry	2
9	Impact de l’épidémie de COVID-19 lors de la 1ère vague sur les patients de la cohorte PSOBIOTEQ traités pour psoriasis cutané 2021 ·PubMed Central ·(unknown), E. Mahé, M.‐A. Richard, (unknown), Yann De Rycke, M. Viguier, M. Beylot‐Barry, A. Dupuy, N. Bénéton, P. Joly, D. Jullien, H. Bachelez, É. Sbidian, O. Chosidow, C. Paul, Florence Tubach	1
10	Apport de la cytométrie de flux médullaire pour le diagnostic de mastocytose systémique 2021 ·C. Bulaï Livideanu, P.A. Apoil, Benoît Lepage, (unknown), (unknown), (unknown), Julien Rossignol, (unknown), (unknown), M. Beylot‐Barry, Stéphane Barète, Ghandi Damaj, C. Paul	0
11	Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts 2021 ·Dermatology ·(unknown), Laëtitia Penso, Viet-Thi Tran, Claire Hotz, Philippe Guillem, A. Villani, Pierre Perrot, (unknown), Eric Jacquet, Aude Nassif, H. Bachelez, P. Wolkenstein, M. Beylot‐Barry, M.‐A. Richard, Philippe Ravaud, M. Viguier, É. Sbidian	5
12	Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology 2021 ·British Journal of Dermatology ·F. Hacard, Bruno Giraudeau, (unknown), (unknown), A.‐P. Jonville‐Béra, (unknown), Bach‐Nga Pham, (unknown), (unknown), B. Guillot, M. Beylot‐Barry, O. Chosidow, A. Maruani	7
13	Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study 2021 ·Journal of Oncology ·(unknown), (unknown), (unknown), L. Dousset, S. Prey, Caroline Dutriaux, Anne Pham‐Ledard, M. Beylot‐Barry, E. Gérard	15
14	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders 2020 ·The American Journal of Surgical Pathology ·(unknown), Nicolás Ortonne, Laura Pelletier, M. Beylot‐Barry, S. Oro, F. Franck, (unknown), Catherine Godfraind, Marie-Hélène Delfau, M. D’Incan, B. Vergier	28
15	Impact of the French guidelines on the prescribing habits of systemic treatments for moderate‐to‐severe psoriasis 2020 ·Journal of the European Academy of Dermatology and Venereology ·A. Villani, F. Amatore, M. Tauber, B. Guillot, M. Viguier, M. Beylot‐Barry, D. Jullien	2
16	Drug‐induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases 2018 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), C. Prost‐Squarcioni, F. Tétart, Benoît Bensaïd, (unknown), M. Beylot‐Barry, V. Descamps, S. Duvert‐Lehembre, S. Grootenboer‐Mignot, G. Jeudy, A. Soria, Marie‐Blanche Valnet‐Rabier, A. Barbaud, F. Caux, Bénédicte Lebrun‐Vignes	39
17	A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma 2014 ·British Journal of Haematology ·Francine M. Foss, Ranjana H. Advani, Madeleine Duvic, Kenneth B. Hymes, Tanin Intragumtornchai, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, Robert J. Belt, Eric D. Jacobsen, Guy Laurent, Dina Ben‐Yehuda, M. Beylot‐Barry, Uwe Hillen, Poul Knoblauch, Gajanan Bhat, Shanta Chawla, Lee F. Allen, Brad Pohlman	161
18	Specific Skin Lesions in Chronic Myelomonocytic Leukemia 2012 ·The American Journal of Surgical Pathology ·(unknown), Bettina Fabiani, Claire Bénet, S. Dalac, B. Balme, Claire Delattre, B. Vergier, M. Beylot‐Barry, (unknown), Nicolás Ortonne, (unknown), A. Carlotti, (unknown), É. Frouin, (unknown), L. Laroche, Ivan Théate, Franck Monnien, Francine Mugneret, Tony Petrella	73
19	Guess what? Wells' syndrome. 1999 ·PubMed ·(unknown), M. Beylot‐Barry, (unknown), (unknown), (unknown)	0
20	Targetoid hemosiderotic hemangioma 1999 ·European Journal of Dermatology ·(unknown), (unknown), B. Vergier, M. Beylot‐Barry, C Beylot	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact